Literature DB >> 7458411

HLA and porphyria cutanea tarda.

L Llorente, R Enríquez de Salamanca, F Campillo, M L Peña.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7458411     DOI: 10.1007/bf00406542

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  4 in total

1.  Familial and sporadic porphyria cutanea: two different diseases.

Authors:  H de Verneuil; G Aitken; Y Nordmann
Journal:  Hum Genet       Date:  1978-10-31       Impact factor: 4.132

2.  Porphyria cutanea tarda in three generations of a single family.

Authors:  A V Benedetto; J P Kushner; J S Taylor
Journal:  N Engl J Med       Date:  1978-02-16       Impact factor: 91.245

3.  An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity.

Authors:  J P Kushner; A J Barbuto; G R Lee
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

4.  Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase.

Authors:  G H Elder; D M Sheppard; R E De Salamanca; A Olmos
Journal:  Clin Sci (Lond)       Date:  1980-06       Impact factor: 6.124

  4 in total
  3 in total

1.  A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association.

Authors:  M Simon; L Le Mignon; R Fauchet; J Yaouanq; V David; G Edan; M Bourel
Journal:  Am J Hum Genet       Date:  1987-08       Impact factor: 11.025

2.  Hepatic acetylator phenotype in porphyria cutanea tarda.

Authors:  J M Ladero; R Enriquez de Salamanca; S Chinarro
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 3.  Recent advances in cancer metabolism: a technological perspective.

Authors:  Yun Pyo Kang; Nathan P Ward; Gina M DeNicola
Journal:  Exp Mol Med       Date:  2018-04-16       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.